US20140051173A1 - Analytical devices for detection of low-quality pharmaceuticals - Google Patents
Analytical devices for detection of low-quality pharmaceuticals Download PDFInfo
- Publication number
- US20140051173A1 US20140051173A1 US13/829,753 US201313829753A US2014051173A1 US 20140051173 A1 US20140051173 A1 US 20140051173A1 US 201313829753 A US201313829753 A US 201313829753A US 2014051173 A1 US2014051173 A1 US 2014051173A1
- Authority
- US
- United States
- Prior art keywords
- product
- pad
- chemical components
- assay
- dietary supplement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 16
- 239000003814 drug Substances 0.000 title description 17
- 239000000126 substance Substances 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000000047 product Substances 0.000 claims abstract description 39
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 26
- 238000003556 assay Methods 0.000 claims description 63
- 239000003153 chemical reaction reagent Substances 0.000 claims description 49
- 238000012360 testing method Methods 0.000 claims description 49
- 239000004480 active ingredient Substances 0.000 claims description 24
- 230000002209 hydrophobic effect Effects 0.000 claims description 20
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 20
- 229940127557 pharmaceutical product Drugs 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 9
- 238000004891 communication Methods 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 238000000151 deposition Methods 0.000 claims description 6
- -1 antibiotic Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 4
- 230000001754 anti-pyretic effect Effects 0.000 claims description 4
- 239000003430 antimalarial agent Substances 0.000 claims description 4
- 239000002221 antipyretic Substances 0.000 claims description 4
- 229940124638 COX inhibitor Drugs 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 230000000078 anti-malarial effect Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 239000003096 antiparasitic agent Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 230000002452 interceptive effect Effects 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 230000002141 anti-parasite Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 238000003908 quality control method Methods 0.000 claims 1
- 239000000123 paper Substances 0.000 description 67
- 239000000203 mixture Substances 0.000 description 37
- 229940079593 drug Drugs 0.000 description 15
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000004888 barrier function Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 238000002483 medication Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 229960003276 erythromycin Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229920001486 SU-8 photoresist Polymers 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000012254 powdered material Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- JCYPECIVGRXBMO-UHFFFAOYSA-N 4-(dimethylamino)azobenzene Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=CC=C1 JCYPECIVGRXBMO-UHFFFAOYSA-N 0.000 description 1
- FZRCKLPSHGTOAU-UHFFFAOYSA-N 6-amino-1,4-dimethylcyclohexa-2,4-diene-1-carbaldehyde Chemical compound CC1=CC(N)C(C)(C=O)C=C1 FZRCKLPSHGTOAU-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- PGNKBEARDDELNB-UHFFFAOYSA-N Diethylcarbamazine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCN(CC)C(=O)N1CCN(C)CC1 PGNKBEARDDELNB-UHFFFAOYSA-N 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- DKNPRRRKHAEUMW-UHFFFAOYSA-N Iodine aqueous Chemical compound [K+].I[I-]I DKNPRRRKHAEUMW-UHFFFAOYSA-N 0.000 description 1
- 206010067997 Iodine deficiency Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229960002669 albendazole Drugs 0.000 description 1
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- INDBQWVYFLTCFF-UHFFFAOYSA-L cobalt(2+);dithiocyanate Chemical compound [Co+2].[S-]C#N.[S-]C#N INDBQWVYFLTCFF-UHFFFAOYSA-L 0.000 description 1
- 239000003283 colorimetric indicator Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 239000003962 counterfeit drug Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960004837 diethylcarbamazine citrate Drugs 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- JGUQDUKBUKFFRO-CIIODKQPSA-N dimethylglyoxime Chemical compound O/N=C(/C)\C(\C)=N\O JGUQDUKBUKFFRO-CIIODKQPSA-N 0.000 description 1
- SXWPCWBFJXDMAI-UHFFFAOYSA-L disodium;3,4,5,6-tetraoxocyclohexene-1,2-diolate Chemical compound [Na+].[Na+].[O-]C1=C([O-])C(=O)C(=O)C(=O)C1=O SXWPCWBFJXDMAI-UHFFFAOYSA-L 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 235000006479 iodine deficiency Nutrition 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 229960003439 mebendazole Drugs 0.000 description 1
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000012249 potassium ferrocyanide Nutrition 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- AWDBHOZBRXWRKS-UHFFFAOYSA-N tetrapotassium;iron(6+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+6].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] AWDBHOZBRXWRKS-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- WRTMQOHKMFDUKX-UHFFFAOYSA-N triiodide Chemical compound I[I-]I WRTMQOHKMFDUKX-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
- G01N21/8483—Investigating reagent band
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/11—Automated chemical analysis
Definitions
- the invention relates to user-friendly analytical devices, in particular, Paper Analytical Devices (PADs), for detection of at least two chemical components indicative of a low quality pharmaceutical product or dietary supplement, and a method of use thereof.
- PADs Paper Analytical Devices
- U.S. Pat. No. 6,136,549 discloses systems for conducting spectrophotometric analysis which includes a chromatographic medium, such as an assay test strip, that is designed to be contacted with a test solution having activated magnetic particles.
- U.S. Pat. No. 6,770,487 discloses “dip stick” style paper-based diagnostic test devices, in which identifying information and the test result are machine-readable.
- 6,847,451 discloses apparatuses for determining the concentration of an analyte in a physiological sample, which include at least one light source, a detector array, means for determining whether a sufficient amount of sample is present on each of the plurality of different areas, and means for determining the concentration of the analyte based on the reflected light detected from those areas determined to have sufficient sample
- U.S. Pat. No. 7,344,081 discloses a method of automatically detecting a test result of a probe zone of a test strip comprising capturing an image of a one-dimensional bar code and an image of at least one test strip from a scanning object, and determining a setting value for the at least one test strip based, at least in part, on said captured image of said bar code.
- U.S. Pat. No. 7,885,444 discloses a method for determining a response of each probe zone on a test strip by selecting an average pixel value of each section of reference white respectively adjacent to the image of a target line to serve as a reference for determining a color response of the target line.
- US Publication No. 2008/0012083 discloses an analytical system-on-a-chip that can be used as an analytical imaging device, for example, for detecting the presence of a chemical compound, which may also include software that can detect and analyze the output signals of the device.
- US Publication No. 2011/0189786 discloses a method of detecting the presence or absence of an analyte in a fluid sample.
- the method includes applying the sample to an inlet zone of a diagnostic system that includes a hydrophilic cotton loading thread to serve as a capillary to deliver a solute to a reagent testing zone, and detecting color change of reagent analyte interaction.
- US Publication No. 2011/0111517 discloses a paper-based microfluidic assay device comprising a porous, hydrophilic substrate; a fluid-impermeable barrier defining a boundary of an assay region and a boundary of a main channel region, the main channel region fluidically connected to the assay region; and a strip of conductive material disposed on the porous, hydrophilic substrate for detecting the concentration/flow of analyte.
- pSiFlow Technology Inc. provides a mobile testing and process management web infrastructure built around its Calibrated Color Match (CCM) image processing technology that enables digital reading of color-based test strips using any mobile phone with a camera.
- CCM Calibrated Color Match
- the World Health Organization reports that many medications for sale in underdeveloped countries are of low quality, which either contain low concentrations of active ingredients that are not sufficient to treat the underlying condition, or contain substitute active ingredients that may have adverse effects on some patients, or have no active ingredients at all; or even contain toxic ingredients. Although the prevalence of such medications is difficult to measure, both the WHO and US Food and Drug Administration (FDA) estimate that 10-30% of all drugs in the developing world are low quality drugs. A consumer taking a low quality pharmaceutical product may die or experience other adverse medical effects from the underlying condition or from contaminants in the pharmaceutical product. The failure of treatment may be mistaken for resistant strains of the disease requiring much more rigorous treatment that can itself endanger the patient. Also, low quality medications that fail to cure the underlying condition may speed up development of actual resistance in pathogens.
- WHO World Health Organization
- the present invention addresses these needs by providing an inexpensive, user-friendly, consistent analytical device capable of detecting various low quality pharmaceutical products and measuring levels of iodine in iodized salt.
- the present invention provides an easy-to-use, inexpensive analytical device, typically a Paper Analytical Device (PAD), for detection or analysis of at least two chemical components in a dosage formulation indicative of a low quality pharmaceutical product or dietary supplement.
- the analytical device typically comprises a multilayer PAD having one or more assay regions of porous, hydrophilic material in communication with a non-chemically interfering binder agent such as parafilm disposed adjacent at least to a hydrophobic layer.
- Vessels containing reagents are in registry with at least one assay region for which testing for a chemical component is desired. Rupture of a vessel wall establishes communication between corresponding assay regions and the reagent released by the ruptured vessel wall.
- the vessel may be a separable tubular member insertable between two layers of the PAD.
- the vessel wall is fabricated from a frangible material.
- the vessel may be integrally formed within the PAD, with the vessel wall including a rupture zone.
- the one or more vessels when ruptured are preferably in fluid communication with the assay region, e.g., directly or by a channel or other structure joining the two. In each example, rupture of the vessel wall releases the reagent contained by the vessel wall.
- a porous, hydrophilic substrate such as a paper may be used for the assay regions.
- the device includes at least one or more of an information identification zone and a color calibration zone. Alternatively, at least one or more of the information identification zone and the color calibration zone may be integrated within the hydrophobic layer or layers.
- the device may further include at least one electronically readable information zone that, after activation of the device, provides color information necessary for detection of the chemical components.
- the electronically readable information zone comprises alignment references for transforming or correcting a captured image of the PAD to facilitate analysis and processing of the color information to more accurately detect the at least two chemical components.
- the alignment references include a plurality of fiducial markers for orienting the captured image.
- the chemical components to be detected by the whole PAD include at least one active ingredient and possibly one or more excipients.
- the active ingredient includes at least one of an anti-malarial, antibiotic, anti-parasitic, cox-inhibitor, analgesic, antipyretic, phosphodiesterase-5 inhibitors, anti-viral, anti-cancer or dietary supplement compound.
- the color information determines whether an inappropriate combination of active ingredient and excipient is present, indicative of a low quality pharmaceutical or dietary supplement product.
- the method comprises providing the multilayer analytical device as disclosed herein and disposing the product to be analyzed into assay regions.
- the device is activated in a manner such that the reagents contact the product to be analyzed in the assay regions to provide color information.
- vessel rupture may establish communication between a reagent and the corresponding assay region.
- the activating of the device includes rupturing of the vessel wall sufficiently to enable release of the reagents therein onto the assay regions.
- the subsequently developed color information is analyzed to detect the presence or absence of the chemical components.
- kits may be provided for detection of at least two chemical components indicative of a low quality pharmaceutical or dietary supplement product.
- the kit comprises, but is not limited to, a multilayer analytical device as disclosed herein and instructions for using the kit.
- the instructions include at least instructions for detecting the presence or absence of the at least two chemical components indicative of a low quality pharmaceutical product or dietary supplement using the kit.
- the instructions may be provided in hard copy, accessible via a link to a website or mobile application, accessible via a QR code or any combination thereof (including any equivalent and complementary instruction formats).
- the kit may also include a solvent that is present in an amount sufficient to dilute the pharmaceutical product to be analyzed to an analyzable concentration.
- PAD as described and shown herein may be provided in singular or plural quantities and may also be provided with one or more other PAD configurations, including, but not limited, to those PAD devices described and shown in co-owned U.S. patent application Ser. No. 13/566,915 and related applications.
- the PAD disclosed and shown herein is readily used for analyzing the quality of a pharmaceutical or nutritional product, such as an iodized table salt.
- FIG. 1 shows an exemplary multilayer paper analytical device (PAD).
- PAD multilayer paper analytical device
- FIG. 2 shows another exemplary multilayer paper analytical device (PAD).
- PAD multilayer paper analytical device
- FIGS. 3 and 3A respectively show operation and assembly of the exemplary multilayer paper analytical device of FIG. 1 .
- FIG. 4 shows an exemplary Erythromycin PAD.
- paper analytical device refers to a composition based on a porous hydrophilic material (such as paper) and comprising areas of hydrophobic barriers which define hydrophilic assay areas.
- the hydrophilic assay areas may include test reagents.
- low quality pharmaceutical product and “dietary supplement product” refers to products purported to be genuine products for treating a disease or disorder or providing a nutritional supplement but containing low concentrations of active ingredients that are not sufficient to treat purported use, a product containing substitute active ingredients that may have undesired side effects compared to the stated drug, a product containing active ingredients that have undergone degradation, or a product having no active ingredients at all.
- these terms include products that contain ingredients that should not be present in a genuine product of the stated type including ingredients that may be toxic.
- active agent refers to a chemical capable of being detected by an analytical device as disclosed herein, such as a PAD.
- the active agent may include chemically active ingredients, excipients or anticipated degradation products within a pharmaceutical formulation.
- a “camera device” refers to a device that contains a camera component.
- Exemplary camera devices are various types of digital cameras and scanners as well as mobile devices such as cell phones, smartphones or similar devices.
- the images will be uploaded to a computer or other electronic device that is capable of transmitting the pictures to another location.
- the phone already generally has the ability to forward the image, e.g., as a text message or as part of an e-mail.
- the present invention provides an easy-to-use, inexpensive analytical device, such as a PAD, for detection of specific chemicals and/or chemical groups in an active ingredient, which is particularly capable of detecting various low quality pharmaceutical and dietary supplement products.
- a PAD a complex metal-oxide-semiconductor
- One advantage of the present invention is that more than one active ingredient can be analyzed with the same device, which is especially useful in analyzing a combination drug.
- binders and fillers that should be present in the stated formulation, e.g., starch as a binder in acetaminophen tablets; and additionally, to screen for a multitude of likely substitute drugs, e.g., an antipyretic in place of expensive anti-malarial drugs, ampicillin in place of erythromycin, and binders or fillers such as gypsum or lactose in place of an active pharmaceutical.
- the analytical device of the invention comprises a porous, hydrophilic medium, preferably a paper such as a fast chromatography paper or an absorbant blotting paper.
- a suitable porous hydrophilic medium includes one that has a fast flow rate via capillary action, has enough absorption capacity to hold adequate amounts of reagent; has durability and stability such that it does not fall apart or fall over when wet; and is compatible with at least one of the methods used to fashion assay regions.
- Characteristics which should be considered when designing an analytical device of the invention, such as a PAD include density, thickness, pH, basis weight, solvent flow-rate through fabricated substrate, compatibility with fabrication methods, pore size, and porosity.
- suitable materials for an analytical device of the invention include, but are not limited to nitrocellulose acetate, chromatography paper, cellulose acetate, cellulosic paper, filter paper, tissue paper, writing paper, paper towel, cloth, and porous polymer film.
- the substrate for a PAD is Whatman 3MM Chr chromatography paper, Ahlstrom 205, Ahlstrom 222, Ahlstrom 226, Ahlstrom 319, or Whatman No. 1 filter paper. In one preferred embodiment. Ahlstrom 319 filter paper is used.
- the final dimension of the PAD can have a length “L”, width “W” and height or depth “H” that can vary, depending on the number and size of assay regions and information zones needed on the PAD.
- the height or depth is determined by the chemistry required to detect various components of a particular low-quality pharmaceutical or dietary supplement product.
- assay regions are defined on the analytical device of the invention, either by affixing individual strips or other shapes cut from paper onto an inert backing material, or by patterning a piece of paper with a hydrophobic barrier substantially permeating the thickness of the paper medium to define the boundaries of the desired assay regions.
- the hydrophilic assay regions or reaction areas with the boundaries defined by the hydrophobic area can be in any suitable size or shape.
- the precise dimensions of the assay regions are determined by the type of reaction to be performed within each assay region, or for optimizing viewing results.
- Suitable shapes for reaction areas include rectangular lanes, circles (or “spots”), stars, squares, triangles, etc. Reaction areas can comprise multiple shapes. For example, a rectangular lane may culminate with a circle.
- each circle can range from about 1.5 cm to about 0.3 cm. Preferably the circles are about 1.0 cm in diameter.
- the length of rectangular lanes can range from about 1 cm to the full length of the PAD, and the width can range from about 0.1 cm to the full width of the PAD.
- the assay regions of the PAD can be produced in a number of ways that are known to one skilled in the art.
- photolithography of a resist such as SU-8 can be used to produce hydrophobic regions within the hydrophilic paper medium according to the procedures laid out in US Publication No. 2011/0111517 A1, which is herein incorporated in its entirety.
- the PAD can be fabricated using wax printing according to the procedures laid out in Lu, Y.; Shi, W.; Jiang, L.; Qin, J. Lin, B. Electrophoresis 2009, 30, p. 1497-1500 and Carrilho, E.; Martinez, A. W., Whitesides, G. M. Anal. Chem. 2009, 81, p.
- an HP ColorQube printer is used to deposit wax ink, preferably black, in the desired regions of Ahlstrom 319 paper according to a template laid out in a computer program such as Adobe Illustrator; alternatively, the template may be stored and printed as an image file such as a PDF.
- the preferred paper type is too thick for wax deposition on one side of the paper to form the necessary continuous hydrophobic barrier, so wax ink must be printed on both sides of the paper, after which the paper is heated to 70-120° C. (preferably 100° C.) to allow the wax to melt through the paper and form a continuous hydrophobic barrier surrounding the desired assay region.
- a wax crayon can be applied heavily around the regions desired on both the front and back of the paper, after which the paper is heated to 70-120° C. (preferably 100° C.) to allow the wax to melt through the paper and form a continuous hydrophobic barrier surrounding the desired assay region.
- the “cut and paste” method requires the lanes to be cut from the hydrophilic paper medium and adhered to a relatively strong backing, mylar plastic for example, using an adhesive. This method does not require the application of a hydrophobic agent in order to define the hydrophilic reaction areas. As a result, the chance of bleed-over of hydrophobic agent into the lanes is eliminated.
- the lanes can be cut using any precise cutter, such as an exacto-knife or craft cutter.
- an exemplary device 10 that employs the “cut and paste” method is shown as a multilayer device employing a non-chemically interfering binder agent such as parafilm 12 to attach unadulterated test strips 14 to at last one laminate backing 16 (as shown herein, parafilm 12 attaches test strips 14 to first laminate backing 16 a ).
- a non-chemically interfering binder agent such as parafilm 12 to attach unadulterated test strips 14 to at last one laminate backing 16 (as shown herein, parafilm 12 attaches test strips 14 to first laminate backing 16 a ).
- One or more vessels 18 are disposed between first and second laminate backings 16 a and 16 b with each vessel having a wall 18 a for containment of an unstable or corrosive reagent 17 therein (see FIGS. 3 and 3A ).
- Vessels 18 may be independent tubular members as shown that are placed in registry with release openings 20 provided in first laminate backing 16 a and in further registry with corresponding release openings 22 in parafilm 12 .
- Release openings 20 and 22 are in registry with those test strips 14 for which testing for a particular chemical compound and/or active agent is desired.
- test strip 14 a may be employed for detecting acetaminophen or vitamin C
- test strip 14 b may be employed for detecting starch or vitamin C.
- a substrate 24 which may be a paper layout may be provided between second laminate backing 16 b and a third laminate backing 16 c , which paper layout includes at least one or more of at least one information identification zone (e.g., at least one electronically readable information zone such as a bar code, QR code or set of fiducial marks) and at least one color calibration zone that are readily observed during use of the device.
- the information identification zone contains information about the PAD-type, serial number and fabrication date and allows for remote identification of the PAD.
- the color calibration zone allows for accurate computer analysis of PAD images taken under varying light conditions. Fiducial markers aid in orienting captured images so that an image software can correct or transform the captured image.
- one or more of the information identification zone, the color calibration zone and the fiducial markers may be provided on any of the backings 16 and that these features may be incorporated on separate layers of device 10 to augment the interchangeability of the layers with one another (for example, providing substrate 24 with the fiducial markers and integrating the information identification and color calibration zones on one or more backings 16 ).
- laminate backings 16 are not limited to the quantity shown, and that fewer or additional laminate backings may be employed as may be amenable for successful testing of detectable chemicals and active agents. It is also understood that the layers shown herein are exemplary, and that the layers may be placed in any order amenable to the successful practice of the device.
- a related device 10 ′ employs the “cut and paste” method in which the vessels and test strips are integrated with a grate 26 on which a chemical or active agent (e.g., in the form of a pill) may be applied.
- Grate 26 may comprise emery paper, cardboard or any other suitable material or structure for deriving a suitable testing sample while ensuring a portable and easily stored device.
- vessel wall 18 may be fabricated from a frangible composite or comparable or equivalent material.
- vessels 18 are shown herein as independently insertable members, it is understood that one or more vessels may be integrated with one or both of laminate backings 16 a and/or 16 b .
- laminate backing 16 a or 16 b may be fabricated to include a vessel integral therewith, thereby obviating the need for two laminate backings to house a vessel therebetween.
- release openings 20 may be replaced by frangible zones (not shown) that are in registry with release openings 22 in parafilm 12 and release reagent 17 upon rupture thereof.
- one or more insertable vessels may be incorporated with one or more vessels integral with device 10 , which may be desirable when testing of different chemicals will be conducted at different times and/or in different locations. Such a configuration may be desirable when employing different reagents having different storage properties.
- Vessels 18 stably house those reagents which may degrade over time when exposed to ambient conditions, such that long-term storage is achieved.
- vessels 18 can be loaded with unstable or corrosive reagents (illustrated generally as reagent 17 ) that are readily released upon compromise of vessel wall 18 a . Because vessels 18 are built into the PAD, they can be broken on-site to release the reagent as needed. Precise lane control as to test strips 14 is thereby maintained while ensuring device requiring minimal packaging and thereby minimal cost.
- the analytical device also contains at least one assay reagent in each of the assay regions.
- a hydrophobic barrier defines independent isolated assay regions of various shapes and at least one of the assay regions includes a reagent or precursor thereof that is capable of identifying a component that should not be present in the pharmaceutical product.
- reagents or regent forming precursors can be optionally loaded into the reaction areas.
- the reagents or precursors can be loaded into the reaction area individually by hand, or via an automated process.
- the regents may be pre-loaded as liquid solutions or suspensions or may be loaded into the vessels.
- Folin-Ciocalteu potassium hexacyano
- reagents may be deposited from aqueous solution or from organic solution.
- acetonitrile is the preferred organic solvent because the wax barriers are not affected by the acetonitrile.
- many colorimetric reagents plateau at particular concentrations so that adding additional reagents will not enhance color results.
- the upper limit on the amount of reagents added is more or less determined by the PAD's loading capacity.
- the volume of the reagent loaded onto the PAD can range from about 2 to about 100 microliters, or from about 10 to about 50 microliters, or preferably from about 20 to about 30 microliters.
- Reagents may be deposited on the surface of the analytical device in many ways that will be familiar to those skilled in the art, including but not limited to the use of: microcapillary pipettes and droppers, single- or multi-channel automatic pipetting devices, rods that can capture a droplet of solution or “frog” type depositors that perform this function with multiple rods simultaneously, dipping or spraying equipment, or solution deposition robots.
- the invention also provides a method for detecting the presence or absence of a chemical and/or a chemical functional group in a composition, or for quantifying the amount of at least one chemical in a composition, or for comparing the amounts of two chemicals present in the composition.
- This method comprises providing a paper analytical device of the invention; disposing the composition into the assay region in a manner such that it contacts the assay reagent or reagents in the assay region; and analyzing the assay region to detect the presence or absence of the chemical and/or the chemical functional group in the composition or to detect the amount of the targeted chemical or chemicals present in the assay region or to compare the amounts of two chemicals present in the composition.
- the chemicals to be detected can be in any suitable formulation, including tablets, pills, solids, or powders.
- Other suitable formulations include liquids, such as suspensions, syrups, or solutions of medications.
- a solid formulation can be used directly with the PAD, by swiping or rubbing the formulation onto the PAD at a specific location(s).
- a solid formulation must be diluted into a liquid solution or suspension in order to be used with the specific PAD.
- Liquid formulations may be added directly to the PAD, or may be further diluted and then added to the PAD.
- a formulation may be used both directly and also as a dilution on the same PAD.
- the PADs can be used to detect low quality human and animal pharmaceutical products, including classes of treating agents such as anti-malarials (artemether, lumifantrine), beta lactam antibiotics (ampicillin, amoxicillin), cox-inhibitors, antiparasitic drugs (albendazole, mebendazole, ivermectin), antipyretics (aspirin, acetaminophen) phosphodiesterase inhibitors (sildenafil citrate), and anti-virals (ostamilvir phosphate). They can also be used to analyze foodstuffs that have been supplemented or fortified with micronutrients (iodine, iron, zinc, vitamin C) or with medications (diethylcarbamazine citrate).
- NSAIDs ibuprofen
- analgesics lidocine
- HMG-CoA reductase inhibitors statins
- ace-inhibitors quinapril
- macrolide antibiotics erythromycin
- anti-anxiety medications alprazolam
- hi-polar disorder and schizophrenia medications olanzapine
- anemia medications epoetin alfa
- anti-retrovirals abacavir
- a drug tablet may be broken in half and rubbed on the surface of the paper in the assay regions, or a rough surface such as a piece of wire or plastic mesh or sandpaper may be used to assist in forming powdered material on the assay regions.
- a solid formulation may be crushed or ground to powder, or a capsule containing powdered material may be opened, and the powder may be spread on the assay region using a paddle or spatula.
- Such deposition of solid material may be carried out with the aid of an assisting device, such as a plastic mesh or plate pierced with holes in regions that correspond to the locations of the assay regions.
- a straight-edge may be drawn across the top surface of the assisting device to pack the composition within the holes of the assisting device, after which the assisting device is lifted from the PAD.
- the composition may be disposed within the assay region by placing a solution or suspension containing the composition drop-wise onto the desired region of the paper analytical device.
- the composition may be disposed within the assay region by dipping part of the PAD into the solution or suspension of the composition and allowing the composition to move into the assay region with the resulting capillary flow.
- the pharmaceutical product is applied directly to the vessel rupture zones where communication with the reagents forms a solution.
- the remaining pharmaceutical product is diluted with solvent and dropped onto the other assay regions.
- the disposing of the solvent into the assay regions typically causes a colorimetric change in each region that can be analyzed to detect the presence/absence of the chemical and/or the chemical functional group in the composition, to quantify the amount of the targeted chemical, or to compare the amounts of two chemicals present in the composition.
- the hydrophobic regions can also define control regions within the hydrophilic paper medium.
- a timer region may be included in order to alert the user when the test has completed.
- the timer region may comprise a color-generating reaction in which one component travels up the lane with the solvent flow and creates a color when it encounters another component at the top of the lane, or it may comprise other timing mechanisms such as delay of the solvent flow by a deposited reagent such as sugars, surfactants, or polymers.
- the PAD may include positive or negative control regions. A negative control may be included in order to verify that the PAD has not become contaminated during storage or use or that the solvent used to develop the colors does not interfere with a color generating reaction.
- a positive control may be included to show that the reagents in a test lane are still viable, or it may be used as a standard for the image analysis software as disclosed hereinbelow.
- the PAD may also contain assay regions whose only function is to demonstrate that the user has complied with instructions for correct use of the PADs, or assay regions whose function is to demonstrate that the PAD is an authentic device and not a counterfeit.
- the paper analytical device contains at least one electronically readable information zone, which provides information necessary for determining the outcome of the test performed on the PAD based on images obtained by a camera device.
- the information zone typically includes appropriate information that is electrically readable per se or after being photographed or otherwise imaged electronically.
- Such information may include an identification tag such as a two-dimensional bar code (e.g., a QR code), color standards, and/or fiducial or alignment marks.
- Each PAD can be imprinted with a two-dimensional barcode such as a Quick Response (QR) barcode that contains the type and serial number of the PAD so that a PAD test can be uniquely identified and the necessary color processing steps to perform the test can be automatically determined, which provides a simple and inexpensive way to uniquely identify the PAD, in addition to providing pertinent information for perspective distortion correction and subsequent color analysis.
- QR Quick Response
- other information can also be encoded in the two-dimensional code image.
- a key task of the image analysis software is the perspective correction or transformation of distorted images, which transforms an image captured at an unknown standoff and optical axis position to a canonical coordinate system in which regions to be analyzed for subsequent color characterization are expressed.
- each PAD may also contain one or more additional fiducial markers such as “finder squares” or rectifiers to eliminate angle and 3D distortions of the PAD's photographed image.
- the identification zone can be placed anywhere on the PAD. Preferably, the identification zone can be printed on the PAD prior to application of hydrophobic regions and the identification zone is located on an upper corner of the PAD.
- the color content of specific regions of the PAD will be analyzed to automatically determine the test result. This removes human subjectivity in color interpretation.
- PAD images may be captured under different ambient lighting conditions and their global effect on PAD color distributions must be suppressed.
- Image analysis software can be used to compare the extracted colors in the PAD image's color calibration zone to known values to identify the specific color correction methods needed.
- white balancing in which the overall brightness of the image is adjusted to force the white square in the PAD image to have a pure white color value.
- the calibration zone can be in any suitable shape, including rectangles, squares, circles, or triangles.
- the sub-regions can be in any suitable shape, including rectangles, squares, circles or triangles.
- the color calibration zone is a rectangle region and the sub-regions are different colored squares.
- the color calibration zone can be printed onto the PAD prior to or after application of hydrophobic regions.
- the calibration zone can be placed anywhere on the PAD.
- the calibration zone is printed on the PAD prior to application of hydrophobic regions and is located on an upper corner of the PAD.
- the PAD of the invention comprises one information zone having a color calibration zone, another information zone having multiple fiducial marks, and yet another information zone comprising a QR code or other identification tag.
- the method further comprises providing a camera device, capturing an image of the PAD that has reacted with the composition using the camera device, and providing an image analysis software capable of using information provided by the information zone and the image of the test result in order to identify and quantify a colorimetric change within the assay region of the paper analytical device shown in the captured image.
- the capture image contains a two-dimensional bar code such as a QR code and one or more fiducial markers.
- the image software identifies the QR code region, separates the image of the PAD's assay regions from background present in the picture, scales, rotates, and performs geometrical transformations on the captured PAD image based on the QR code and the one or more fiducial markers, aligns the PAD assay regions with stored images in the database, reads test results from pre-specified locations in the stored assay regions, and classifies the test results.
- the method of the invention further comprises compiling a database of the captured images of the paper analytical devices and the computed test outcomes, wherein the two-dimensional barcode is a QR code that allows for automated identification of a specific PAD including the PAD-type, serial number and fabrication date.
- the image analysis software is provided on the camera device for processing the captured image in situ.
- the image analysis software may be provided on a network server such that the captured image is processed by sending the picture to the network server that performs the analysis and transmits the results back to the camera device.
- the hydrophobic regions can also define control regions within the hydrophilic paper medium.
- a timer region may be included in order to alert the user when the test has completed.
- the time region may comprise a colorimetric indicator.
- the PAD may include positive or negative control regions.
- a negative control may be included in order to verify the purity of the reaction solvent.
- a positive control may be included in order to verify the presence (or absence) of the chemical to be detected.
- the control substrates if any, may be included in the paper medium at the time the other colorimetric reagents are added to the paper medium.
- the PAD may also contain hydrophilic regions for titrations and/or reverse titrations, as well as user compliance lanes for improving the accuracy of the quantitative analysis of the chemicals.
- the PADs may be packaged in kits providing a user with all of the materials necessary for using the PAD.
- the kit may contain a solvent (such as deionized water or ethanol), a plastic micropipette, weighing paper, and a cotton swab.
- Instructions may be provided in hard copy, accessible via a link to a website or mobile application, accessible via a QR code or any combination thereof (including any equivalent and complementary instruction formats).
- the PADs comprising test reagents may be subjected to degradation due to temperature, light, or moisture which may affect the accuracy of the tests performed. As a result, the PADs may be individually packaged and sealed in light- and moisture-resistant packets.
- the packets may be packaged with a desiccant in order to maintain a specific moisture level, and remove excess moisture.
- a kit for detecting the presence/absence of a chemical and/or a chemical functional group in a composition, quantifying a chemical in a composition, or measuring the relative amounts of two materials present in a composition includes a PAD as disclosed herein; a solvent sufficient to saturate the paper assay device; and instructions for detecting the presence/absence of a chemical and/or a chemical functional group in a composition, quantifying a chemical in a composition, or measuring the relative amounts of two materials present in a composition.
- the solvent is one that is sufficient to dissolve or suspend the composition containing the chemical and/or the chemical functional group to be analyzed.
- the kit contains a dish to hold the solvent and a spatula swab, or pipette for applying the composition onto the PAD.
- FIG. 4 shows an exemplary embodiment of an Erythromycin PAD 30 comprising a color calibration zone 32 , an identification zone 34 , reaction areas as well as a timer region.
- PAD 30 includes a “red flag” wheel 36 having a plurality of spokes 36 a wherein each spoke is customizable with different chemicals to test for unique excipients and counterfeiting agents. The specific type of chemical in each spoke can be selected depending upon where the test is being conducted as well as to anticipate the types of counterfeit drugs that may be in use in such areas.
- Reaction areas 38 , 40 , 42 , 44 , 46 and 48 work in concert to perform a quantitative and qualitative assessment of the active ingredient and possible counterfeiting agents.
- HCl and Bromocresol green at area 38 works in conjunction with HCl and Methyl yellow at area 40 to help determine the concentration of Erythromycin.
- Ninhydrin at area 42 detects counterfeiting agents with primary or secondary amines.
- Sodium nitroprusside-acetylaldehyde at area 44 detects the presence of amines and counterfeiting agents.
- phenol treated paper over a capillary containing sulfuric acid detects and differentiates between certain reducing sugars when activated colorimetrically.
- ferric iron in glacial acetic acid and concentrated sulfuric acid contained in a glass capillary under glass fiber paper, detects the presence of macrolide rings when activated. It is understood that testing is not constrained by the examples disclosed herein. For instance, wheel 36 and spokes 36 a thereof may be customizable along with the reaction areas to proactively combat changes in counterfeiting efforts. As counterfeiters recognize the testing patters of a PAD 30 and alter their products according, PAD 30 can be customized with alternative testing reagents in anticipation of the alteration of counterfeit products.
- the color changes of the PAD regions of interest are identified to determine a qualitative or qualitative test result. While the precise amount of active agent may not be identified, the brightness or intensity of the assaying region can provide some indication of the relative amount of active agent that is present in the product tested.
- the PADs are developed as business-card sized testing systems that can help determine the authenticity of a suspicious pharmaceutical. Paper, or another absorbant material, is impregnated with a colorimetric reagent(s) that will indicate when a particular chemical or functional group is present.
- the assay regions of the PAD were produced in a number of ways that are known to one skilled in the art:
- the paper medium is saturated with a crosslinking photoresist and then exposed to UV radiation in a pattern, creating hydrophobic and hydrophilic zones thereby.
- a modified inkjet printer places hydrophobic barriers of black wax to create lanes. The PAD is then heated to ensure full permeation through the paper.
- the multilayer cut and paste design uses parafilm to attach unadulterated test strips to a laminate backing (e.g., as shown and described herein with respect to FIG. 1 ).
- Capillaries are loaded with unstable or corrosive reagents that are built into the PAD so that they can be broken on-site to release the reagent (e.g., as shown and described herein with respect to FIGS. 3 and 3A ).
- Cost of reagents and labor were assumed to be approximately equal and therefore ignored for the purposes of this analysis.
Landscapes
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Plasma & Fusion (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
- The invention relates to user-friendly analytical devices, in particular, Paper Analytical Devices (PADs), for detection of at least two chemical components indicative of a low quality pharmaceutical product or dietary supplement, and a method of use thereof.
- User-friendly analytical devices such as Paper Analytical Devices (PADs) are known in the art as convenient and inexpensive means for assaying chemicals. As these devices contain all necessary reagents and do not require power, they are easy to operate in a field setting. U.S. Pat. No. 6,136,549 discloses systems for conducting spectrophotometric analysis which includes a chromatographic medium, such as an assay test strip, that is designed to be contacted with a test solution having activated magnetic particles. U.S. Pat. No. 6,770,487 discloses “dip stick” style paper-based diagnostic test devices, in which identifying information and the test result are machine-readable. U.S. Pat. No. 6,847,451 discloses apparatuses for determining the concentration of an analyte in a physiological sample, which include at least one light source, a detector array, means for determining whether a sufficient amount of sample is present on each of the plurality of different areas, and means for determining the concentration of the analyte based on the reflected light detected from those areas determined to have sufficient sample, U.S. Pat. No. 7,344,081 discloses a method of automatically detecting a test result of a probe zone of a test strip comprising capturing an image of a one-dimensional bar code and an image of at least one test strip from a scanning object, and determining a setting value for the at least one test strip based, at least in part, on said captured image of said bar code. U.S. Pat. No. 7,885,444 discloses a method for determining a response of each probe zone on a test strip by selecting an average pixel value of each section of reference white respectively adjacent to the image of a target line to serve as a reference for determining a color response of the target line. US Publication No. 2008/0012083 discloses an analytical system-on-a-chip that can be used as an analytical imaging device, for example, for detecting the presence of a chemical compound, which may also include software that can detect and analyze the output signals of the device. US Publication No. 2011/0189786 discloses a method of detecting the presence or absence of an analyte in a fluid sample. The method includes applying the sample to an inlet zone of a diagnostic system that includes a hydrophilic cotton loading thread to serve as a capillary to deliver a solute to a reagent testing zone, and detecting color change of reagent analyte interaction. US Publication No. 2011/0111517 discloses a paper-based microfluidic assay device comprising a porous, hydrophilic substrate; a fluid-impermeable barrier defining a boundary of an assay region and a boundary of a main channel region, the main channel region fluidically connected to the assay region; and a strip of conductive material disposed on the porous, hydrophilic substrate for detecting the concentration/flow of analyte. In a commercial embodiment, pSiFlow Technology Inc. provides a mobile testing and process management web infrastructure built around its Calibrated Color Match (CCM) image processing technology that enables digital reading of color-based test strips using any mobile phone with a camera.
- The World Health Organization (WHO) reports that many medications for sale in underdeveloped countries are of low quality, which either contain low concentrations of active ingredients that are not sufficient to treat the underlying condition, or contain substitute active ingredients that may have adverse effects on some patients, or have no active ingredients at all; or even contain toxic ingredients. Although the prevalence of such medications is difficult to measure, both the WHO and US Food and Drug Administration (FDA) estimate that 10-30% of all drugs in the developing world are low quality drugs. A consumer taking a low quality pharmaceutical product may die or experience other adverse medical effects from the underlying condition or from contaminants in the pharmaceutical product. The failure of treatment may be mistaken for resistant strains of the disease requiring much more rigorous treatment that can itself endanger the patient. Also, low quality medications that fail to cure the underlying condition may speed up development of actual resistance in pathogens.
- Multiple factors contribute to the prevalence of low quality pharmaceutical products in developing countries. First of all, manufacturing and selling low quality pharmaceutical products are both easy and hugely lucrative, and low quality products can enter the supply chain at many points. Moreover, buyers and consumers cannot assess identity or quality of pharmaceutical products. Furthermore, manufacturing low quality pharmaceutical products is not a serious crime in many countries, and there is a low risk of detection from official agencies and organizations. Finally, the time, expertise, and expense required for testing pharmaceutical products is a particular barrier to effective post-market surveillance of pharmaceuticals in developing countries.
- Some medical conditions arise not from a pathogen, but from a deficiency in an essential nutrient. For example, widespread iodine deficiency is a problem in many underdeveloped countries that is associated with developmental impairment in children. Fortification of table salt with potassium iodate or potassium iodide is a common route to address this problem. However, production and distribution methods for iodized table salt in many developing countries yield inadequate or inconsistent levels of iodine. Unfortunately, the time and expense of testing for iodized table salt deters manufacturers, distributors, and end-users from testing iodized table salt to determine iodine concentrations. Thus, a low-cost method of testing iodized table salt at the production facility or in the field is needed to determine whether the salt is adequately fortified with iodine within therapeutic concentrations recommended by the WHO.
- Thus, there exist long-felt needs for a low-cost, easy-to-use, reliable, minimalistic chemical means of detecting low quality pharmaceutical products and dietary supplements such as iodized salt. These quality problems are also present for veterinary medications and nutritional supplements for animals. The present invention addresses these needs by providing an inexpensive, user-friendly, consistent analytical device capable of detecting various low quality pharmaceutical products and measuring levels of iodine in iodized salt.
- The present invention provides an easy-to-use, inexpensive analytical device, typically a Paper Analytical Device (PAD), for detection or analysis of at least two chemical components in a dosage formulation indicative of a low quality pharmaceutical product or dietary supplement. The analytical device typically comprises a multilayer PAD having one or more assay regions of porous, hydrophilic material in communication with a non-chemically interfering binder agent such as parafilm disposed adjacent at least to a hydrophobic layer. Vessels containing reagents are in registry with at least one assay region for which testing for a chemical component is desired. Rupture of a vessel wall establishes communication between corresponding assay regions and the reagent released by the ruptured vessel wall.
- The vessel may be a separable tubular member insertable between two layers of the PAD. In this exemplary embodiment, the vessel wall is fabricated from a frangible material. Alternatively, the vessel may be integrally formed within the PAD, with the vessel wall including a rupture zone. The one or more vessels when ruptured are preferably in fluid communication with the assay region, e.g., directly or by a channel or other structure joining the two. In each example, rupture of the vessel wall releases the reagent contained by the vessel wall.
- A porous, hydrophilic substrate such as a paper may be used for the assay regions. The device includes at least one or more of an information identification zone and a color calibration zone. Alternatively, at least one or more of the information identification zone and the color calibration zone may be integrated within the hydrophobic layer or layers.
- The device may further include at least one electronically readable information zone that, after activation of the device, provides color information necessary for detection of the chemical components. The electronically readable information zone comprises alignment references for transforming or correcting a captured image of the PAD to facilitate analysis and processing of the color information to more accurately detect the at least two chemical components. The alignment references include a plurality of fiducial markers for orienting the captured image.
- The chemical components to be detected by the whole PAD include at least one active ingredient and possibly one or more excipients. The active ingredient includes at least one of an anti-malarial, antibiotic, anti-parasitic, cox-inhibitor, analgesic, antipyretic, phosphodiesterase-5 inhibitors, anti-viral, anti-cancer or dietary supplement compound. The color information determines whether an inappropriate combination of active ingredient and excipient is present, indicative of a low quality pharmaceutical or dietary supplement product.
- Also provided is a method for detection of at least two chemical components indicative of a low quality pharmaceutical or dietary supplement product. The method comprises providing the multilayer analytical device as disclosed herein and disposing the product to be analyzed into assay regions. The device is activated in a manner such that the reagents contact the product to be analyzed in the assay regions to provide color information. In some cases, vessel rupture may establish communication between a reagent and the corresponding assay region. Generally, the activating of the device includes rupturing of the vessel wall sufficiently to enable release of the reagents therein onto the assay regions. The subsequently developed color information is analyzed to detect the presence or absence of the chemical components.
- Additionally, a kit may be provided for detection of at least two chemical components indicative of a low quality pharmaceutical or dietary supplement product. The kit comprises, but is not limited to, a multilayer analytical device as disclosed herein and instructions for using the kit. The instructions include at least instructions for detecting the presence or absence of the at least two chemical components indicative of a low quality pharmaceutical product or dietary supplement using the kit. The instructions may be provided in hard copy, accessible via a link to a website or mobile application, accessible via a QR code or any combination thereof (including any equivalent and complementary instruction formats). The kit may also include a solvent that is present in an amount sufficient to dilute the pharmaceutical product to be analyzed to an analyzable concentration.
- The PAD as described and shown herein may be provided in singular or plural quantities and may also be provided with one or more other PAD configurations, including, but not limited, to those PAD devices described and shown in co-owned U.S. patent application Ser. No. 13/566,915 and related applications.
- The PAD disclosed and shown herein is readily used for analyzing the quality of a pharmaceutical or nutritional product, such as an iodized table salt.
- Further features of the invention, its nature and various advantages will be more apparent from the following detailed description, taken in conjunction with the accompanying drawings in which like reference characters refer to like parts throughout and in which:
-
FIG. 1 shows an exemplary multilayer paper analytical device (PAD). -
FIG. 2 shows another exemplary multilayer paper analytical device (PAD). -
FIGS. 3 and 3A respectively show operation and assembly of the exemplary multilayer paper analytical device ofFIG. 1 . -
FIG. 4 shows an exemplary Erythromycin PAD. - As used herein, “paper analytical device” (or “PAD”) refers to a composition based on a porous hydrophilic material (such as paper) and comprising areas of hydrophobic barriers which define hydrophilic assay areas. The hydrophilic assay areas may include test reagents.
- As used herein, “low quality pharmaceutical product” and “dietary supplement product” refers to products purported to be genuine products for treating a disease or disorder or providing a nutritional supplement but containing low concentrations of active ingredients that are not sufficient to treat purported use, a product containing substitute active ingredients that may have undesired side effects compared to the stated drug, a product containing active ingredients that have undergone degradation, or a product having no active ingredients at all. In addition, these terms include products that contain ingredients that should not be present in a genuine product of the stated type including ingredients that may be toxic.
- As used herein, “active agent” refers to a chemical capable of being detected by an analytical device as disclosed herein, such as a PAD. The active agent may include chemically active ingredients, excipients or anticipated degradation products within a pharmaceutical formulation.
- As used herein, a “camera device” refers to a device that contains a camera component. Exemplary camera devices are various types of digital cameras and scanners as well as mobile devices such as cell phones, smartphones or similar devices. When digital cameras are used, the images will be uploaded to a computer or other electronic device that is capable of transmitting the pictures to another location. Of course, when a picture or image is taken from a mobile phone, the phone already generally has the ability to forward the image, e.g., as a text message or as part of an e-mail.
- The present invention provides an easy-to-use, inexpensive analytical device, such as a PAD, for detection of specific chemicals and/or chemical groups in an active ingredient, which is particularly capable of detecting various low quality pharmaceutical and dietary supplement products. One advantage of the present invention is that more than one active ingredient can be analyzed with the same device, which is especially useful in analyzing a combination drug. Moreover, in addition to verification of an appropriate active ingredient that should be present, it is also possible to screen for binders and fillers that should be present in the stated formulation, e.g., starch as a binder in acetaminophen tablets; and additionally, to screen for a multitude of likely substitute drugs, e.g., an antipyretic in place of expensive anti-malarial drugs, ampicillin in place of erythromycin, and binders or fillers such as gypsum or lactose in place of an active pharmaceutical.
- Porous Hydrophilic Substrate
- Typically, the analytical device of the invention comprises a porous, hydrophilic medium, preferably a paper such as a fast chromatography paper or an absorbant blotting paper. A suitable porous hydrophilic medium includes one that has a fast flow rate via capillary action, has enough absorption capacity to hold adequate amounts of reagent; has durability and stability such that it does not fall apart or fall over when wet; and is compatible with at least one of the methods used to fashion assay regions. Characteristics which should be considered when designing an analytical device of the invention, such as a PAD, include density, thickness, pH, basis weight, solvent flow-rate through fabricated substrate, compatibility with fabrication methods, pore size, and porosity. Examples of suitable materials for an analytical device of the invention, such as a PAD, include, but are not limited to nitrocellulose acetate, chromatography paper, cellulose acetate, cellulosic paper, filter paper, tissue paper, writing paper, paper towel, cloth, and porous polymer film. In one embodiment, the substrate for a PAD is Whatman 3MM Chr chromatography paper, Ahlstrom 205, Ahlstrom 222, Ahlstrom 226, Ahlstrom 319, or Whatman No. 1 filter paper. In one preferred embodiment. Ahlstrom 319 filter paper is used.
- Fabrication of the PAD and Assay Regions Thereupon
- The final dimension of the PAD can have a length “L”, width “W” and height or depth “H” that can vary, depending on the number and size of assay regions and information zones needed on the PAD. The height or depth is determined by the chemistry required to detect various components of a particular low-quality pharmaceutical or dietary supplement product.
- Several assay regions are defined on the analytical device of the invention, either by affixing individual strips or other shapes cut from paper onto an inert backing material, or by patterning a piece of paper with a hydrophobic barrier substantially permeating the thickness of the paper medium to define the boundaries of the desired assay regions. The hydrophilic assay regions or reaction areas with the boundaries defined by the hydrophobic area can be in any suitable size or shape. The precise dimensions of the assay regions are determined by the type of reaction to be performed within each assay region, or for optimizing viewing results. Suitable shapes for reaction areas include rectangular lanes, circles (or “spots”), stars, squares, triangles, etc. Reaction areas can comprise multiple shapes. For example, a rectangular lane may culminate with a circle. The diameter of each circle can range from about 1.5 cm to about 0.3 cm. Preferably the circles are about 1.0 cm in diameter. The length of rectangular lanes can range from about 1 cm to the full length of the PAD, and the width can range from about 0.1 cm to the full width of the PAD.
- The assay regions of the PAD can be produced in a number of ways that are known to one skilled in the art. For example, photolithography of a resist such as SU-8 can be used to produce hydrophobic regions within the hydrophilic paper medium according to the procedures laid out in US Publication No. 2011/0111517 A1, which is herein incorporated in its entirety. Alternately, the PAD can be fabricated using wax printing according to the procedures laid out in Lu, Y.; Shi, W.; Jiang, L.; Qin, J. Lin,
B. Electrophoresis 2009, 30, p. 1497-1500 and Carrilho, E.; Martinez, A. W., Whitesides, G. M. Anal. Chem. 2009, 81, p. 7091-7095, which are herein incorporated in their entireties. In a preferred embodiment, an HP ColorQube printer is used to deposit wax ink, preferably black, in the desired regions of Ahlstrom 319 paper according to a template laid out in a computer program such as Adobe Illustrator; alternatively, the template may be stored and printed as an image file such as a PDF. The preferred paper type is too thick for wax deposition on one side of the paper to form the necessary continuous hydrophobic barrier, so wax ink must be printed on both sides of the paper, after which the paper is heated to 70-120° C. (preferably 100° C.) to allow the wax to melt through the paper and form a continuous hydrophobic barrier surrounding the desired assay region. For prototyping, a wax crayon can be applied heavily around the regions desired on both the front and back of the paper, after which the paper is heated to 70-120° C. (preferably 100° C.) to allow the wax to melt through the paper and form a continuous hydrophobic barrier surrounding the desired assay region. - The “cut and paste” method requires the lanes to be cut from the hydrophilic paper medium and adhered to a relatively strong backing, mylar plastic for example, using an adhesive. This method does not require the application of a hydrophobic agent in order to define the hydrophilic reaction areas. As a result, the chance of bleed-over of hydrophobic agent into the lanes is eliminated. The lanes can be cut using any precise cutter, such as an exacto-knife or craft cutter.
- Referring to
FIG. 1 , anexemplary device 10 that employs the “cut and paste” method is shown as a multilayer device employing a non-chemically interfering binder agent such asparafilm 12 to attachunadulterated test strips 14 to at last one laminate backing 16 (as shown herein,parafilm 12 attachestest strips 14 to first laminate backing 16 a). One ormore vessels 18 are disposed between first and secondlaminate backings 16 a and 16 b with each vessel having awall 18 a for containment of an unstable orcorrosive reagent 17 therein (seeFIGS. 3 and 3A ).Vessels 18 may be independent tubular members as shown that are placed in registry withrelease openings 20 provided in first laminate backing 16 a and in further registry withcorresponding release openings 22 inparafilm 12.Release openings test strips 14 for which testing for a particular chemical compound and/or active agent is desired. For example, test strip 14 a may be employed for detecting acetaminophen or vitamin C, whiletest strip 14 b may be employed for detecting starch or vitamin C. - A
substrate 24 which may be a paper layout may be provided between second laminate backing 16 b and a third laminate backing 16 c, which paper layout includes at least one or more of at least one information identification zone (e.g., at least one electronically readable information zone such as a bar code, QR code or set of fiducial marks) and at least one color calibration zone that are readily observed during use of the device. The information identification zone contains information about the PAD-type, serial number and fabrication date and allows for remote identification of the PAD. The color calibration zone allows for accurate computer analysis of PAD images taken under varying light conditions. Fiducial markers aid in orienting captured images so that an image software can correct or transform the captured image. It is understood that one or more of the information identification zone, the color calibration zone and the fiducial markers may be provided on any of thebackings 16 and that these features may be incorporated on separate layers ofdevice 10 to augment the interchangeability of the layers with one another (for example, providingsubstrate 24 with the fiducial markers and integrating the information identification and color calibration zones on one or more backings 16). - It is understood that
laminate backings 16 are not limited to the quantity shown, and that fewer or additional laminate backings may be employed as may be amenable for successful testing of detectable chemicals and active agents. It is also understood that the layers shown herein are exemplary, and that the layers may be placed in any order amenable to the successful practice of the device. - Referring further to
FIG. 2 , arelated device 10′ employs the “cut and paste” method in which the vessels and test strips are integrated with agrate 26 on which a chemical or active agent (e.g., in the form of a pill) may be applied.Grate 26 may comprise emery paper, cardboard or any other suitable material or structure for deriving a suitable testing sample while ensuring a portable and easily stored device. - When
vessels 18 are independent members insertable betweenlaminate backings 16 a and 16 b,vessel wall 18 may be fabricated from a frangible composite or comparable or equivalent material. Althoughvessels 18 are shown herein as independently insertable members, it is understood that one or more vessels may be integrated with one or both of laminate backings 16 a and/or 16 b. For example, eitherlaminate backing 16 a or 16 b may be fabricated to include a vessel integral therewith, thereby obviating the need for two laminate backings to house a vessel therebetween. In this example,release openings 20 may be replaced by frangible zones (not shown) that are in registry withrelease openings 22 inparafilm 12 andrelease reagent 17 upon rupture thereof. Also, one or more insertable vessels may be incorporated with one or more vessels integral withdevice 10, which may be desirable when testing of different chemicals will be conducted at different times and/or in different locations. Such a configuration may be desirable when employing different reagents having different storage properties. -
Vessels 18 stably house those reagents which may degrade over time when exposed to ambient conditions, such that long-term storage is achieved. Referring further toFIGS. 3 and 3A ,vessels 18 can be loaded with unstable or corrosive reagents (illustrated generally as reagent 17) that are readily released upon compromise ofvessel wall 18 a. Becausevessels 18 are built into the PAD, they can be broken on-site to release the reagent as needed. Precise lane control as to teststrips 14 is thereby maintained while ensuring device requiring minimal packaging and thereby minimal cost. - Reagents and Reagent Deposition
- The analytical device also contains at least one assay reagent in each of the assay regions. In one embodiment, a hydrophobic barrier defines independent isolated assay regions of various shapes and at least one of the assay regions includes a reagent or precursor thereof that is capable of identifying a component that should not be present in the pharmaceutical product.
- Various reagents or regent forming precursors can be optionally loaded into the reaction areas. The reagents or precursors can be loaded into the reaction area individually by hand, or via an automated process. The regents may be pre-loaded as liquid solutions or suspensions or may be loaded into the vessels. Examples of reagent materials suitable for use in the analytical device of invention such as a PAD include, but are not limited to, Folin-Ciocalteu, potassium hexacyanoferrate(II) trihydrate, iodine-potassium iodide reagent, universal indicator, ferric chloride, triiodide, triiodide-starch complex, soluble starch; cationic, anionic, and neutral pH indicators; barium chloride, sodium rhodizonate, potassium hexacyanoferrate(II), NaOH, tosic acid, potassium carbonate, citric acid, copper sulfate, sodium tetraphenylborate, cobalt thiocyanate, ammonium molybdate, nitroaniline, 1,2-napthaquinone-4-sulfonate, dimethylglyoxime, and paradimethylaminobenzaldehyde. These reagents may be deposited from aqueous solution or from organic solution. For wax printed PADs, acetonitrile is the preferred organic solvent because the wax barriers are not affected by the acetonitrile. Surprisingly, many colorimetric reagents plateau at particular concentrations so that adding additional reagents will not enhance color results. Thus, the upper limit on the amount of reagents added is more or less determined by the PAD's loading capacity. The volume of the reagent loaded onto the PAD can range from about 2 to about 100 microliters, or from about 10 to about 50 microliters, or preferably from about 20 to about 30 microliters.
- Reagents may be deposited on the surface of the analytical device in many ways that will be familiar to those skilled in the art, including but not limited to the use of: microcapillary pipettes and droppers, single- or multi-channel automatic pipetting devices, rods that can capture a droplet of solution or “frog” type depositors that perform this function with multiple rods simultaneously, dipping or spraying equipment, or solution deposition robots.
- General Method of Use
- The invention also provides a method for detecting the presence or absence of a chemical and/or a chemical functional group in a composition, or for quantifying the amount of at least one chemical in a composition, or for comparing the amounts of two chemicals present in the composition. This method comprises providing a paper analytical device of the invention; disposing the composition into the assay region in a manner such that it contacts the assay reagent or reagents in the assay region; and analyzing the assay region to detect the presence or absence of the chemical and/or the chemical functional group in the composition or to detect the amount of the targeted chemical or chemicals present in the assay region or to compare the amounts of two chemicals present in the composition.
- Compositions Suitable for Analysis
- The chemicals to be detected can be in any suitable formulation, including tablets, pills, solids, or powders. Other suitable formulations include liquids, such as suspensions, syrups, or solutions of medications. In some instances, a solid formulation can be used directly with the PAD, by swiping or rubbing the formulation onto the PAD at a specific location(s). In other instances, a solid formulation must be diluted into a liquid solution or suspension in order to be used with the specific PAD. Liquid formulations may be added directly to the PAD, or may be further diluted and then added to the PAD. In some instances, a formulation may be used both directly and also as a dilution on the same PAD.
- The PADs can be used to detect low quality human and animal pharmaceutical products, including classes of treating agents such as anti-malarials (artemether, lumifantrine), beta lactam antibiotics (ampicillin, amoxicillin), cox-inhibitors, antiparasitic drugs (albendazole, mebendazole, ivermectin), antipyretics (aspirin, acetaminophen) phosphodiesterase inhibitors (sildenafil citrate), and anti-virals (ostamilvir phosphate). They can also be used to analyze foodstuffs that have been supplemented or fortified with micronutrients (iodine, iron, zinc, vitamin C) or with medications (diethylcarbamazine citrate). However, other classes of active agents are also contemplated, such as NSAIDs (ibuprofen), analgesics (lidocine), HMG-CoA reductase inhibitors (statins), ace-inhibitors (quinapril), macrolide antibiotics (erythromycin), anti-anxiety medications (alprazolam), hi-polar disorder and schizophrenia medications (olanzapine), anemia medications (epoetin alfa), and anti-retrovirals (abacavir), etc. Specific PADs and their application are disclosed herein.
- Deposition of the Composition to be Analyzed on the PAD and Activation of the PAD Tests
- In one embodiment, a drug tablet may be broken in half and rubbed on the surface of the paper in the assay regions, or a rough surface such as a piece of wire or plastic mesh or sandpaper may be used to assist in forming powdered material on the assay regions. Alternatively, a solid formulation may be crushed or ground to powder, or a capsule containing powdered material may be opened, and the powder may be spread on the assay region using a paddle or spatula. Such deposition of solid material may be carried out with the aid of an assisting device, such as a plastic mesh or plate pierced with holes in regions that correspond to the locations of the assay regions. In order to deposit a controlled amount of the composition to be analyzed, a straight-edge may be drawn across the top surface of the assisting device to pack the composition within the holes of the assisting device, after which the assisting device is lifted from the PAD. The composition may be disposed within the assay region by placing a solution or suspension containing the composition drop-wise onto the desired region of the paper analytical device. Alternatively, the composition may be disposed within the assay region by dipping part of the PAD into the solution or suspension of the composition and allowing the composition to move into the assay region with the resulting capillary flow.
- In the preferred embodiment, the pharmaceutical product is applied directly to the vessel rupture zones where communication with the reagents forms a solution. The remaining pharmaceutical product is diluted with solvent and dropped onto the other assay regions.
- General Method of Analysis of the Test Results
- Once the composition has been applied to the assay regions, the disposing of the solvent into the assay regions typically causes a colorimetric change in each region that can be analyzed to detect the presence/absence of the chemical and/or the chemical functional group in the composition, to quantify the amount of the targeted chemical, or to compare the amounts of two chemicals present in the composition.
- The hydrophobic regions can also define control regions within the hydrophilic paper medium. For example, a timer region may be included in order to alert the user when the test has completed. The timer region may comprise a color-generating reaction in which one component travels up the lane with the solvent flow and creates a color when it encounters another component at the top of the lane, or it may comprise other timing mechanisms such as delay of the solvent flow by a deposited reagent such as sugars, surfactants, or polymers. Additionally, the PAD may include positive or negative control regions. A negative control may be included in order to verify that the PAD has not become contaminated during storage or use or that the solvent used to develop the colors does not interfere with a color generating reaction. A positive control may be included to show that the reagents in a test lane are still viable, or it may be used as a standard for the image analysis software as disclosed hereinbelow. The PAD may also contain assay regions whose only function is to demonstrate that the user has complied with instructions for correct use of the PADs, or assay regions whose function is to demonstrate that the PAD is an authentic device and not a counterfeit.
- Information Identification Zone
- The paper analytical device contains at least one electronically readable information zone, which provides information necessary for determining the outcome of the test performed on the PAD based on images obtained by a camera device. The information zone typically includes appropriate information that is electrically readable per se or after being photographed or otherwise imaged electronically. Such information may include an identification tag such as a two-dimensional bar code (e.g., a QR code), color standards, and/or fiducial or alignment marks.
- Each PAD can be imprinted with a two-dimensional barcode such as a Quick Response (QR) barcode that contains the type and serial number of the PAD so that a PAD test can be uniquely identified and the necessary color processing steps to perform the test can be automatically determined, which provides a simple and inexpensive way to uniquely identify the PAD, in addition to providing pertinent information for perspective distortion correction and subsequent color analysis. Depending on the application, other information can also be encoded in the two-dimensional code image. A key task of the image analysis software is the perspective correction or transformation of distorted images, which transforms an image captured at an unknown standoff and optical axis position to a canonical coordinate system in which regions to be analyzed for subsequent color characterization are expressed. The origin and basis vectors for this coordinate system can be automatically calculated from the position of “finder marks” or fiducial marks on the QR code. In some embodiments, each PAD may also contain one or more additional fiducial markers such as “finder squares” or rectifiers to eliminate angle and 3D distortions of the PAD's photographed image. The identification zone can be placed anywhere on the PAD. Preferably, the identification zone can be printed on the PAD prior to application of hydrophobic regions and the identification zone is located on an upper corner of the PAD.
- Color Calibration Zone
- In analyzing a PAD, the color content of specific regions of the PAD will be analyzed to automatically determine the test result. This removes human subjectivity in color interpretation. However, PAD images may be captured under different ambient lighting conditions and their global effect on PAD color distributions must be suppressed. Thus, it is important to perform color calibration using the color calibration zone on the PAD, which consists of different colored sub-regions, including a white region and a black region. Image analysis software can be used to compare the extracted colors in the PAD image's color calibration zone to known values to identify the specific color correction methods needed. One such method is white balancing, in which the overall brightness of the image is adjusted to force the white square in the PAD image to have a pure white color value. The calibration zone can be in any suitable shape, including rectangles, squares, circles, or triangles. The sub-regions can be in any suitable shape, including rectangles, squares, circles or triangles. Preferably, the color calibration zone is a rectangle region and the sub-regions are different colored squares. The color calibration zone can be printed onto the PAD prior to or after application of hydrophobic regions. The calibration zone can be placed anywhere on the PAD. Preferably, the calibration zone is printed on the PAD prior to application of hydrophobic regions and is located on an upper corner of the PAD.
- In the preferred embodiment, the PAD of the invention comprises one information zone having a color calibration zone, another information zone having multiple fiducial marks, and yet another information zone comprising a QR code or other identification tag.
- The method further comprises providing a camera device, capturing an image of the PAD that has reacted with the composition using the camera device, and providing an image analysis software capable of using information provided by the information zone and the image of the test result in order to identify and quantify a colorimetric change within the assay region of the paper analytical device shown in the captured image. In the preferred embodiment of the method of the invention, the capture image contains a two-dimensional bar code such as a QR code and one or more fiducial markers. The image software identifies the QR code region, separates the image of the PAD's assay regions from background present in the picture, scales, rotates, and performs geometrical transformations on the captured PAD image based on the QR code and the one or more fiducial markers, aligns the PAD assay regions with stored images in the database, reads test results from pre-specified locations in the stored assay regions, and classifies the test results. The method of the invention further comprises compiling a database of the captured images of the paper analytical devices and the computed test outcomes, wherein the two-dimensional barcode is a QR code that allows for automated identification of a specific PAD including the PAD-type, serial number and fabrication date.
- In one embodiment, the image analysis software is provided on the camera device for processing the captured image in situ. Alternatively, the image analysis software may be provided on a network server such that the captured image is processed by sending the picture to the network server that performs the analysis and transmits the results back to the camera device.
- Controls
- The hydrophobic regions can also define control regions within the hydrophilic paper medium. For example, a timer region may be included in order to alert the user when the test has completed. The time region may comprise a colorimetric indicator. Additionally, the PAD may include positive or negative control regions. A negative control may be included in order to verify the purity of the reaction solvent. A positive control may be included in order to verify the presence (or absence) of the chemical to be detected. The control substrates, if any, may be included in the paper medium at the time the other colorimetric reagents are added to the paper medium. The PAD may also contain hydrophilic regions for titrations and/or reverse titrations, as well as user compliance lanes for improving the accuracy of the quantitative analysis of the chemicals.
- Kits
- The PADs may be packaged in kits providing a user with all of the materials necessary for using the PAD. For example, the kit may contain a solvent (such as deionized water or ethanol), a plastic micropipette, weighing paper, and a cotton swab. Instructions may be provided in hard copy, accessible via a link to a website or mobile application, accessible via a QR code or any combination thereof (including any equivalent and complementary instruction formats). The PADs comprising test reagents may be subjected to degradation due to temperature, light, or moisture which may affect the accuracy of the tests performed. As a result, the PADs may be individually packaged and sealed in light- and moisture-resistant packets. Additionally, the packets may be packaged with a desiccant in order to maintain a specific moisture level, and remove excess moisture. Another embodiment of the invention is a kit for detecting the presence/absence of a chemical and/or a chemical functional group in a composition, quantifying a chemical in a composition, or measuring the relative amounts of two materials present in a composition. Typically, the kit includes a PAD as disclosed herein; a solvent sufficient to saturate the paper assay device; and instructions for detecting the presence/absence of a chemical and/or a chemical functional group in a composition, quantifying a chemical in a composition, or measuring the relative amounts of two materials present in a composition. Preferably, the solvent is one that is sufficient to dissolve or suspend the composition containing the chemical and/or the chemical functional group to be analyzed. Typically, the kit contains a dish to hold the solvent and a spatula swab, or pipette for applying the composition onto the PAD.
- The exemplary “cut and paste”
devices FIG. 4 , for example, shows an exemplary embodiment of anErythromycin PAD 30 comprising acolor calibration zone 32, anidentification zone 34, reaction areas as well as a timer region.PAD 30 includes a “red flag”wheel 36 having a plurality ofspokes 36 a wherein each spoke is customizable with different chemicals to test for unique excipients and counterfeiting agents. The specific type of chemical in each spoke can be selected depending upon where the test is being conducted as well as to anticipate the types of counterfeit drugs that may be in use in such areas. If a spoke turns a different color when activated, such color change is indicative of the presence of a counterfeiting agent.Reaction areas exemplary PAD 30, HCl and Bromocresol green atarea 38 works in conjunction with HCl and Methyl yellow atarea 40 to help determine the concentration of Erythromycin. Ninhydrin atarea 42 detects counterfeiting agents with primary or secondary amines. Sodium nitroprusside-acetylaldehyde atarea 44 detects the presence of amines and counterfeiting agents. Atarea 46, phenol treated paper over a capillary containing sulfuric acid detects and differentiates between certain reducing sugars when activated colorimetrically. Atarea 48, ferric iron in glacial acetic acid and concentrated sulfuric acid, contained in a glass capillary under glass fiber paper, detects the presence of macrolide rings when activated. It is understood that testing is not constrained by the examples disclosed herein. For instance,wheel 36 andspokes 36 a thereof may be customizable along with the reaction areas to proactively combat changes in counterfeiting efforts. As counterfeiters recognize the testing patters of aPAD 30 and alter their products according,PAD 30 can be customized with alternative testing reagents in anticipation of the alteration of counterfeit products. - Lastly, the color changes of the PAD regions of interest are identified to determine a qualitative or qualitative test result. While the precise amount of active agent may not be identified, the brightness or intensity of the assaying region can provide some indication of the relative amount of active agent that is present in the product tested.
- An illustration of the invention and a comparison of its advantages over other devices appears below.
- During the development of the Erythromycin PAD, it became necessary to create a new method for PAD fabrication. The paper had to be unadulterated, and the PAD had to be compatible with organic solvents. It was also necessary to develop a method of stabilizing certain reagents for long term storage. To this end, the Cut & Paste/Capillary Method was developed.
- The PADs are developed as business-card sized testing systems that can help determine the authenticity of a suspicious pharmaceutical. Paper, or another absorbant material, is impregnated with a colorimetric reagent(s) that will indicate when a particular chemical or functional group is present.
- The assay regions of the PAD were produced in a number of ways that are known to one skilled in the art:
- The paper medium is saturated with a crosslinking photoresist and then exposed to UV radiation in a pattern, creating hydrophobic and hydrophilic zones thereby.
- A modified inkjet printer places hydrophobic barriers of black wax to create lanes. The PAD is then heated to ensure full permeation through the paper.
- The multilayer cut and paste design uses parafilm to attach unadulterated test strips to a laminate backing (e.g., as shown and described herein with respect to
FIG. 1 ). Capillaries are loaded with unstable or corrosive reagents that are built into the PAD so that they can be broken on-site to release the reagent (e.g., as shown and described herein with respect toFIGS. 3 and 3A ). - Cost of reagents and labor were assumed to be approximately equal and therefore ignored for the purposes of this analysis.
-
TABLE 1 SU-8: Paper: $0.07 per PAD (4,800 PADs per 100 sheet pack - $290.00) SU-8 photo resist: $1.315 per PAD Total: $1.36 per PAD Wax: Paper: $0.09 per PAD (3,200 PADs per 100 sheet pack - $290.00) Monochrome Wax Printing: $0.03 per PAD Total: $0.12 per PAD Cut & Paste: Paper: $0.013 per PAD (18,728 PADs per 100 sheet pack - $290.00) Laminate: $0.032 per PAD (450 PADS per 50 sheet pack - $14.85) Printer Paper: $0.002 per PAD (4,500 PADs per 500 sheets pack - $10.00) Parafilm: $0.034 per PAD (2,602 PADs per 250′ × 4″ pack - $89.10) Total: $0.08 per PAD -
TABLE 2 Observed Assets and Limitations SU-8 Wax Cut & Paste/Capillary ASSETS Precise lane Somewhat Very versatile control bio- degradable Rigid Unadult- Can use multiple types erated of absorbant material paper Insensitive to Precise lane control most temperature conditions Unadulterated paper Rigid Can be easily scaled up Needs less packaging Insensitive to most temperature conditions Lowest cost LIMITA- Cannot be used for Cannot use Not biodegradable TIONS acid sensitive organic analytes solvents One type of paper One type More involved of paper fabrication method Not biodegradable Lack of precise lane control Adulterated paper Not rigid (“floppy”) More involved Needs fabrication method significant packaging More difficult to Sensitive to scale up very warm temperature conditions Needs significant packaging Relatively higher cost - For the sake of brevity, it should be understood that certain structures and functionality, or aspects thereof, of embodiments of the presently disclosed invention that are evident from the illustrations of the figures have not been necessarily restated herein. Also, additional features relating to the use of the present invention can be found in U.S. patent application Ser. No. 13/566,915, filed Aug. 3, 2012, the entire disclosure of which is expressly incorporated herein by reference herein.
- It is to be understood that the presently disclosed invention is not to be limited to the exact configurations as illustrated and described herein. To those of ordinary skill in the art, one or more inventions will be understood to be contemplated from the present application. Accordingly, all expedient modifications readily attainable by one of ordinary skill in the art from the disclosure set forth herein, or by routine experimentation there from, are deemed to be within the spirit and scope of the invention as defined by the appended claims.
Claims (16)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/829,753 US9557274B2 (en) | 2012-08-17 | 2013-03-14 | Analytical devices for detection of low-quality pharmaceuticals |
US15/254,186 US10119981B2 (en) | 2012-08-17 | 2016-09-01 | Analytical devices for detection of low-quality pharmaceuticals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261684570P | 2012-08-17 | 2012-08-17 | |
US13/829,753 US9557274B2 (en) | 2012-08-17 | 2013-03-14 | Analytical devices for detection of low-quality pharmaceuticals |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/254,186 Continuation-In-Part US10119981B2 (en) | 2012-08-17 | 2016-09-01 | Analytical devices for detection of low-quality pharmaceuticals |
Publications (2)
Publication Number | Publication Date |
---|---|
US20140051173A1 true US20140051173A1 (en) | 2014-02-20 |
US9557274B2 US9557274B2 (en) | 2017-01-31 |
Family
ID=50100304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/829,753 Active 2035-05-23 US9557274B2 (en) | 2012-08-17 | 2013-03-14 | Analytical devices for detection of low-quality pharmaceuticals |
Country Status (1)
Country | Link |
---|---|
US (1) | US9557274B2 (en) |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2990118A1 (en) * | 2014-08-25 | 2016-03-02 | Xerox Corporation | Design of paper sensor |
US20160125600A1 (en) * | 2014-11-04 | 2016-05-05 | Samsung Electronics Co., Ltd. | Method of and apparatus for measuring biometric information |
KR20160052442A (en) * | 2014-11-04 | 2016-05-12 | 삼성전자주식회사 | Method and apparatus for measuring biometric information |
WO2017140686A1 (en) * | 2016-02-17 | 2017-08-24 | Axagarius Gmbh & Co. Kg | Measuring system for colorimetric assays |
WO2018089315A1 (en) * | 2016-11-08 | 2018-05-17 | Reliant Immune Diagnostics, LLC | System and method for image analysis of medical test results |
US10024834B2 (en) * | 2016-10-21 | 2018-07-17 | Trace Eye-D, Llc | Devices and methods for detecting an explosive substance |
US10031120B2 (en) * | 2016-10-21 | 2018-07-24 | Trace Eye-D, Llc | Devices and methods for detecting an explosive substance |
US10274433B1 (en) * | 2015-09-30 | 2019-04-30 | Vium, Inc. | Device and method of measuring animal health |
US10331924B2 (en) | 2016-12-14 | 2019-06-25 | Reliant Immune Diagnostics, Inc. | System and method for audiovisual response to retail diagnostic product |
US10473659B2 (en) | 2016-10-17 | 2019-11-12 | Reliant Immune Diagnostics, Inc. | System and method for immediate health assessment response system |
US10527555B2 (en) | 2016-12-14 | 2020-01-07 | Reliant Immune Disgnostics, Inc. | System and method for visual trigger to perform diagnostic test |
US10631031B2 (en) | 2016-12-14 | 2020-04-21 | Reliant Immune Diagnostics, Inc. | System and method for television network in response to input |
US10636527B2 (en) | 2018-06-06 | 2020-04-28 | Reliant Immune Diagnostics, Inc. | System and method for quantifying, ensuring, and triggering the prescriptive authority for a telemedicine session |
US10902951B2 (en) | 2016-10-17 | 2021-01-26 | Reliant Immune Diagnostics, Inc. | System and method for machine learning application for providing medical test results using visual indicia |
US10930381B2 (en) | 2017-11-10 | 2021-02-23 | Reliant Immune Diagnostics, Inc. | Microfluidic testing system for mobile veterinary applications |
US10930380B2 (en) | 2017-11-10 | 2021-02-23 | Reliant Immune Diagnostics, Inc. | Communication loop and record loop system for parallel/serial dual microfluidic chip |
DE102019123474A1 (en) * | 2019-09-02 | 2021-03-04 | Testo SE & Co. KGaA | Method for evaluating a color indicator |
US11041185B2 (en) | 2017-11-10 | 2021-06-22 | Reliant Immune Diagnostics, Inc. | Modular parallel/serial dual microfluidic chip |
US11107585B2 (en) | 2016-10-17 | 2021-08-31 | Reliant Immune Diagnostics, Inc | System and method for a digital consumer medical wallet and storehouse |
US20210272330A1 (en) * | 2014-03-31 | 2021-09-02 | Healthy.Io Ltd. | Methods and apparatus for enhancing color vision and quantifying color interpretation |
US11112406B2 (en) | 2018-06-15 | 2021-09-07 | Reliant Immune Diagnostics, Inc. | System and method for digital remote primary, secondary, and tertiary color calibration via smart device in analysis of medical test results |
US11125749B2 (en) | 2018-06-06 | 2021-09-21 | Reliant Immune Diagnostics, Inc. | System and method for remote colorimetry and ratiometric comparison and quantification in analysis of medical test results |
US11124821B2 (en) | 2017-11-10 | 2021-09-21 | Reliant Immune Diagnostics, Inc. | Microfluidic testing system with cell capture/analysis regions for processing in a parallel and serial manner |
US11125746B2 (en) | 2016-12-14 | 2021-09-21 | Reliant Immune Diagnostics, Inc. | Two-sided flow-through immunoassay |
US11164680B2 (en) | 2016-12-14 | 2021-11-02 | Reliant Immune Diagnostics, Inc. | System and method for initiating telemedicine conference using self-diagnostic test |
US11170877B2 (en) | 2016-12-14 | 2021-11-09 | Reliant Immune Diagnostics, LLC | System and method for correlating retail testing product to medical diagnostic code |
US11200986B2 (en) | 2017-11-10 | 2021-12-14 | Reliant Immune Diagnostics, Inc. | Database and machine learning in response to parallel serial dual microfluidic chip |
US11232872B2 (en) | 2018-06-06 | 2022-01-25 | Reliant Immune Diagnostics, Inc. | Code trigger telemedicine session |
US11295859B2 (en) | 2016-12-14 | 2022-04-05 | Reliant Immune Diagnostics, Inc. | System and method for handing diagnostic test results to telemedicine provider |
US20220146408A1 (en) * | 2017-02-17 | 2022-05-12 | MFB Fertility, Inc. | Method for detection and interpretation of results indicated on a photographed diagnostic test |
US11397152B1 (en) | 2015-09-30 | 2022-07-26 | Recursion Pharmaceuticals, Inc. | Device and method of measuring animal urine |
US11437142B2 (en) | 2017-11-10 | 2022-09-06 | Reliant Immune Diagnostics, Inc. | Biofluidic triggering system and method |
US11527324B2 (en) | 2017-11-10 | 2022-12-13 | Reliant Immune Diagnostics, Inc. | Artificial intelligence response system based on testing with parallel/serial dual microfluidic chip |
US20230045755A1 (en) * | 2020-04-22 | 2023-02-09 | Paul J Gilbert | Fluid characteristic indicator |
US11579145B2 (en) | 2016-10-17 | 2023-02-14 | Reliant Immune Diagnostics, Inc. | System and method for image analysis of medical test results |
US11594337B2 (en) | 2016-12-14 | 2023-02-28 | Reliant Immune Diagnostics, Inc. | System and method for advertising in response to diagnostic test results |
US11599908B2 (en) | 2016-12-14 | 2023-03-07 | Reliant Immune Diagnostics, Inc. | System and method for advertising in response to diagnostic test |
US11651866B2 (en) | 2016-10-17 | 2023-05-16 | Reliant Immune Diagnostics, Inc. | System and method for real-time insurance quote in response to a self-diagnostic test |
WO2023096129A1 (en) * | 2021-11-26 | 2023-06-01 | 주식회사 큐에스택 | Image-based diagnosis system and control method therefor |
US11693002B2 (en) | 2016-10-17 | 2023-07-04 | Reliant Immune Diagnostics, Inc. | System and method for variable function mobile application for providing medical test results using visual indicia to determine medical test function type |
US11802868B2 (en) | 2016-10-17 | 2023-10-31 | Reliant Immune Diagnostics, Inc. | System and method for variable function mobile application for providing medical test results |
US11915810B2 (en) | 2016-12-14 | 2024-02-27 | Reliant Immune Diagnostics, Inc. | System and method for transmitting prescription to pharmacy using self-diagnostic test and telemedicine |
US12009078B2 (en) | 2016-10-17 | 2024-06-11 | Reliant Immune Diagnostics, Inc. | System and method for medical escalation and intervention that is a direct result of a remote diagnostic test |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9933359B2 (en) * | 2014-06-23 | 2018-04-03 | Xerox Corporation | Vendor exclusivity security feature for paper-based diagnostic solution |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136549A (en) | 1999-10-15 | 2000-10-24 | Feistel; Christopher C. | systems and methods for performing magnetic chromatography assays |
US6770487B2 (en) | 2001-05-01 | 2004-08-03 | Ischemia Technologies, Inc. | Bar code readable diagnostic strip test |
US6847451B2 (en) | 2002-05-01 | 2005-01-25 | Lifescan, Inc. | Apparatuses and methods for analyte concentration determination |
TWI340829B (en) | 2002-12-27 | 2011-04-21 | Transpacific Systems Llc | Method for determining a response of each probe zone on a test strip |
US7097103B2 (en) | 2003-05-22 | 2006-08-29 | Wen-Chao Tseng | Method of automatically detecting a test result of a probe zone of a test strip |
US7777287B2 (en) | 2006-07-12 | 2010-08-17 | Micron Technology, Inc. | System and apparatus providing analytical device based on solid state image sensor |
US8921118B2 (en) | 2008-03-27 | 2014-12-30 | President And Fellows Of Harvard College | Paper-based microfluidic systems |
US8206992B2 (en) | 2008-03-27 | 2012-06-26 | President And Fellows Of Harvard College | Cotton thread as a low-cost multi-assay diagnostic platform |
US8590791B2 (en) | 2009-07-07 | 2013-11-26 | Chemspectra, Inc. | Color coded swipe for portable explosive or drug detection system |
-
2013
- 2013-03-14 US US13/829,753 patent/US9557274B2/en active Active
Non-Patent Citations (1)
Title |
---|
, Li et al., "A perspective on paper-based microfluidics: Current status and future trends", Biomicrofluidics, 2012, v. 6, pp. 011301-1-011301-13. * |
Cited By (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210272330A1 (en) * | 2014-03-31 | 2021-09-02 | Healthy.Io Ltd. | Methods and apparatus for enhancing color vision and quantifying color interpretation |
RU2698818C2 (en) * | 2014-08-25 | 2019-08-30 | Зирокс Корпорейшн | Paper sensitive element design |
KR20160024780A (en) * | 2014-08-25 | 2016-03-07 | 제록스 코포레이션 | Design of paper sensor |
CN105388143A (en) * | 2014-08-25 | 2016-03-09 | 施乐公司 | Design of paper sensor |
KR102266347B1 (en) * | 2014-08-25 | 2021-06-18 | 제록스 코포레이션 | Design of paper sensor |
EP2990118A1 (en) * | 2014-08-25 | 2016-03-02 | Xerox Corporation | Design of paper sensor |
KR102199462B1 (en) * | 2014-11-04 | 2021-01-06 | 삼성전자주식회사 | Method and apparatus for measuring biometric information |
EP3018470A1 (en) * | 2014-11-04 | 2016-05-11 | Samsung Electronics Co., Ltd. | Method of and apparatus for measuring biometric information |
US20160125600A1 (en) * | 2014-11-04 | 2016-05-05 | Samsung Electronics Co., Ltd. | Method of and apparatus for measuring biometric information |
CN105572110A (en) * | 2014-11-04 | 2016-05-11 | 三星电子株式会社 | A method of and an apparatus for measuring biometric information |
US10055837B2 (en) * | 2014-11-04 | 2018-08-21 | Samsung Electronics Co., Ltd. | Method of and apparatus for measuring biometric information |
KR20160052442A (en) * | 2014-11-04 | 2016-05-12 | 삼성전자주식회사 | Method and apparatus for measuring biometric information |
US11397152B1 (en) | 2015-09-30 | 2022-07-26 | Recursion Pharmaceuticals, Inc. | Device and method of measuring animal urine |
US10274433B1 (en) * | 2015-09-30 | 2019-04-30 | Vium, Inc. | Device and method of measuring animal health |
WO2017140686A1 (en) * | 2016-02-17 | 2017-08-24 | Axagarius Gmbh & Co. Kg | Measuring system for colorimetric assays |
US11693002B2 (en) | 2016-10-17 | 2023-07-04 | Reliant Immune Diagnostics, Inc. | System and method for variable function mobile application for providing medical test results using visual indicia to determine medical test function type |
US11651866B2 (en) | 2016-10-17 | 2023-05-16 | Reliant Immune Diagnostics, Inc. | System and method for real-time insurance quote in response to a self-diagnostic test |
US11935657B2 (en) | 2016-10-17 | 2024-03-19 | Reliant Immune Diagnostics, Inc. | System and method for a digital consumer medical wallet and storehouse |
US11802868B2 (en) | 2016-10-17 | 2023-10-31 | Reliant Immune Diagnostics, Inc. | System and method for variable function mobile application for providing medical test results |
US12009078B2 (en) | 2016-10-17 | 2024-06-11 | Reliant Immune Diagnostics, Inc. | System and method for medical escalation and intervention that is a direct result of a remote diagnostic test |
US11107585B2 (en) | 2016-10-17 | 2021-08-31 | Reliant Immune Diagnostics, Inc | System and method for a digital consumer medical wallet and storehouse |
US11468991B2 (en) | 2016-10-17 | 2022-10-11 | Reliant Immune Diagnostics, Inc. | System and method for machine learning application for providing medical test results using visual indicia |
US10473659B2 (en) | 2016-10-17 | 2019-11-12 | Reliant Immune Diagnostics, Inc. | System and method for immediate health assessment response system |
US10902951B2 (en) | 2016-10-17 | 2021-01-26 | Reliant Immune Diagnostics, Inc. | System and method for machine learning application for providing medical test results using visual indicia |
US10928390B2 (en) | 2016-10-17 | 2021-02-23 | Reliant Immune Diagnostics, Inc. | Medical apparatus for testing for medical conditions including zika and pregnancy |
US11579145B2 (en) | 2016-10-17 | 2023-02-14 | Reliant Immune Diagnostics, Inc. | System and method for image analysis of medical test results |
US11567070B2 (en) | 2016-10-17 | 2023-01-31 | Reliant Immune Diagnostics, Inc. | System and method for collection and dissemination of biologic sample test results data |
US10031120B2 (en) * | 2016-10-21 | 2018-07-24 | Trace Eye-D, Llc | Devices and methods for detecting an explosive substance |
US10024834B2 (en) * | 2016-10-21 | 2018-07-17 | Trace Eye-D, Llc | Devices and methods for detecting an explosive substance |
US10746717B2 (en) * | 2016-10-21 | 2020-08-18 | Trace Eye-D, Llc | Devices and methods for detecting an explosive substance |
WO2018089315A1 (en) * | 2016-11-08 | 2018-05-17 | Reliant Immune Diagnostics, LLC | System and method for image analysis of medical test results |
US10527555B2 (en) | 2016-12-14 | 2020-01-07 | Reliant Immune Disgnostics, Inc. | System and method for visual trigger to perform diagnostic test |
US10331924B2 (en) | 2016-12-14 | 2019-06-25 | Reliant Immune Diagnostics, Inc. | System and method for audiovisual response to retail diagnostic product |
US11120235B2 (en) | 2016-12-14 | 2021-09-14 | Reliant Immune Diagnostics, Inc. | System and method for audiovisual response to retail diagnostic product |
US11594337B2 (en) | 2016-12-14 | 2023-02-28 | Reliant Immune Diagnostics, Inc. | System and method for advertising in response to diagnostic test results |
US11682207B2 (en) | 2016-12-14 | 2023-06-20 | Reliant Immune Diagnostics, Inc. | System and method for audiovisual response to retail diagnostic product |
US11125746B2 (en) | 2016-12-14 | 2021-09-21 | Reliant Immune Diagnostics, Inc. | Two-sided flow-through immunoassay |
US11164680B2 (en) | 2016-12-14 | 2021-11-02 | Reliant Immune Diagnostics, Inc. | System and method for initiating telemedicine conference using self-diagnostic test |
US11170877B2 (en) | 2016-12-14 | 2021-11-09 | Reliant Immune Diagnostics, LLC | System and method for correlating retail testing product to medical diagnostic code |
US11867635B2 (en) | 2016-12-14 | 2024-01-09 | Reliant Immune Diagnostics, Inc. | System and method for visual trigger to perform diagnostic test |
US11915810B2 (en) | 2016-12-14 | 2024-02-27 | Reliant Immune Diagnostics, Inc. | System and method for transmitting prescription to pharmacy using self-diagnostic test and telemedicine |
US11295859B2 (en) | 2016-12-14 | 2022-04-05 | Reliant Immune Diagnostics, Inc. | System and method for handing diagnostic test results to telemedicine provider |
US11599908B2 (en) | 2016-12-14 | 2023-03-07 | Reliant Immune Diagnostics, Inc. | System and method for advertising in response to diagnostic test |
US10890534B2 (en) | 2016-12-14 | 2021-01-12 | Reliant Immune Diagnostics, Inc. | System and method for visual trigger to perform diagnostic test |
US10635870B2 (en) | 2016-12-14 | 2020-04-28 | Reliant Immune Diagnostics, Inc. | System and method for audiovisual response to retail diagnostic product |
US10631031B2 (en) | 2016-12-14 | 2020-04-21 | Reliant Immune Diagnostics, Inc. | System and method for television network in response to input |
US20220146408A1 (en) * | 2017-02-17 | 2022-05-12 | MFB Fertility, Inc. | Method for detection and interpretation of results indicated on a photographed diagnostic test |
US12061196B2 (en) * | 2017-02-17 | 2024-08-13 | MFB Fertility, Inc. | Method for detection and interpretation of results indicated on a photographed diagnostic test |
US11437142B2 (en) | 2017-11-10 | 2022-09-06 | Reliant Immune Diagnostics, Inc. | Biofluidic triggering system and method |
US10930381B2 (en) | 2017-11-10 | 2021-02-23 | Reliant Immune Diagnostics, Inc. | Microfluidic testing system for mobile veterinary applications |
US11587658B2 (en) | 2017-11-10 | 2023-02-21 | Reliant Immune Diagnostics, Inc. | Communication loop and record loop system for parallel/serial dual microfluidic chip |
US10930380B2 (en) | 2017-11-10 | 2021-02-23 | Reliant Immune Diagnostics, Inc. | Communication loop and record loop system for parallel/serial dual microfluidic chip |
US11527324B2 (en) | 2017-11-10 | 2022-12-13 | Reliant Immune Diagnostics, Inc. | Artificial intelligence response system based on testing with parallel/serial dual microfluidic chip |
US11605450B2 (en) | 2017-11-10 | 2023-03-14 | Reliant Immune Diagnostics, Inc. | Microfluidic testing system for mobile veterinary applications |
US11041185B2 (en) | 2017-11-10 | 2021-06-22 | Reliant Immune Diagnostics, Inc. | Modular parallel/serial dual microfluidic chip |
US11200986B2 (en) | 2017-11-10 | 2021-12-14 | Reliant Immune Diagnostics, Inc. | Database and machine learning in response to parallel serial dual microfluidic chip |
US11124821B2 (en) | 2017-11-10 | 2021-09-21 | Reliant Immune Diagnostics, Inc. | Microfluidic testing system with cell capture/analysis regions for processing in a parallel and serial manner |
US11232872B2 (en) | 2018-06-06 | 2022-01-25 | Reliant Immune Diagnostics, Inc. | Code trigger telemedicine session |
US10636527B2 (en) | 2018-06-06 | 2020-04-28 | Reliant Immune Diagnostics, Inc. | System and method for quantifying, ensuring, and triggering the prescriptive authority for a telemedicine session |
US11125749B2 (en) | 2018-06-06 | 2021-09-21 | Reliant Immune Diagnostics, Inc. | System and method for remote colorimetry and ratiometric comparison and quantification in analysis of medical test results |
US11112406B2 (en) | 2018-06-15 | 2021-09-07 | Reliant Immune Diagnostics, Inc. | System and method for digital remote primary, secondary, and tertiary color calibration via smart device in analysis of medical test results |
US11836949B2 (en) | 2019-09-02 | 2023-12-05 | Testo SE & Co. KGaA | Method for evaluating a color indicator |
DE102019123474A1 (en) * | 2019-09-02 | 2021-03-04 | Testo SE & Co. KGaA | Method for evaluating a color indicator |
US20230045755A1 (en) * | 2020-04-22 | 2023-02-09 | Paul J Gilbert | Fluid characteristic indicator |
WO2023096129A1 (en) * | 2021-11-26 | 2023-06-01 | 주식회사 큐에스택 | Image-based diagnosis system and control method therefor |
Also Published As
Publication number | Publication date |
---|---|
US9557274B2 (en) | 2017-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9557274B2 (en) | Analytical devices for detection of low-quality pharmaceuticals | |
US20130034908A1 (en) | Analytical devices for detection of low-quality pharmaceuticals | |
Noviana et al. | Emerging applications of paper-based analytical devices for drug analysis: A review | |
US10119981B2 (en) | Analytical devices for detection of low-quality pharmaceuticals | |
Sharifi et al. | A 3D origami paper-based analytical device combined with PVC membrane for colorimetric assay of heavy metal ions: Application to determination of Cu (II) in water samples | |
US20150160245A1 (en) | Ppm quantification of iodate using paper device | |
Luka et al. | Portable device for the detection of colorimetric assays | |
EP3710810B1 (en) | Sample carrier for optical measurements | |
Hiraoka et al. | based device for naked eye urinary albumin/creatinine ratio evaluation | |
US10345244B2 (en) | Diagnostic test device with patterned material spots | |
RU2728427C2 (en) | Apparatus and system for collecting and analyzing steam condensate, in particular an exhaled air condensate, as well as a method for use thereof | |
Mathaweesansurn et al. | Simple and fast fabrication of microfluidic paper-based analytical device by contact stamping for multiple-point standard addition assay: Application to direct analysis of urinary creatinine | |
CN101578520B (en) | Based on formed pattern porous medium cross flow and through biometric apparatus, and preparation method thereof and using method | |
KR101954783B1 (en) | Testing apparatus | |
CA2667702C (en) | Lateral flow and flow-through bioassay devices based on patterned porous media, methods of making same, and methods of using same | |
US10486154B2 (en) | Microfluidic device | |
Sharma et al. | Advances in paper-analytical methods for pharmaceutical analysis | |
Ariza-Avidad et al. | Printed disposable colorimetric array for metal ion discrimination | |
AU2003232337A1 (en) | Fluorescence reference plate | |
Phadungcharoen et al. | Smartphone-based Ellman’s colourimetric methods for the analysis of d-penicillamine formulation and thiolated polymer | |
Rahbar et al. | High-throughput deposition of chemical reagents via pen-plotting technique for microfluidic paper-based analytical devices | |
Sruthi et al. | Eco-friendly pH detecting paper-based analytical device: Towards process intensification | |
EP2905607A1 (en) | Analyte detection methods and devices | |
CN102460127A (en) | Device and method for the verification and quantitative analysis of analytes, particularly mycotoxins | |
JP2021128067A (en) | Analysis device, analysis system, and analysis method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ST. MARY'S COLLEGE, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARSTIS, TONI L.O.;BEVILAQUA, MARY M.;REEL/FRAME:030622/0823 Effective date: 20130313 |
|
AS | Assignment |
Owner name: ST. MARY'S COLLEGE, INDIANA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE MISSPELLING OF THE 2ND INVENTOR'S LAST NAME FROM "BEVILAQUA" TO --BEVILACQUA-- PREVIOUSLY RECORDED ON REEL 030622 FRAME 0823. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNOR'S INTEREST;ASSIGNORS:BARSTIS, TONI L.O.;BEVILACQUA, MARY M.;REEL/FRAME:036584/0912 Effective date: 20130313 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: SURCHARGE FOR LATE PAYMENT, SMALL ENTITY (ORIGINAL EVENT CODE: M2554); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |